Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment
Open Access
- 1 October 2001
- journal article
- research article
- Published by BMJ in Archives of Disease in Childhood
- Vol. 85 (4) , 321-325
- https://doi.org/10.1136/adc.85.4.321
Abstract
AIMS To examine the clinical and biological features of acute lymphoblastic leukaemia in children with Down's syndrome (DS), to compare their survival with other children, and to determine if entry to trials and survival has improved. METHODS Examination of presenting features and response to treatment in patients treated in two consecutive national trials, MRC UKALL X and XI. RESULTS The proportion of children with DS was significantly higher in UKALL XI (1.9%) than UKALL X (0.9%). Children with DS tended to be under 10 years and to have the common ALL subtype. Cytogenetic analysis showed that favourable features, such as high hyperdiploidy and t(12;21) were less frequent but also that there was a lack of translocations associated with a poor prognosis. Children with DS showed no increase in risk of relapse at any site but their survival and event free survival were inferior to other children. These results were caused by an increased number of infective deaths during remission (11% compared to 2%). At five years overall survival was 73% in DS children compared with 82% in other children; event free survival was 53% compared to 63% in non-DS children. CONCLUSIONS Entry of children with DS to national trials has increased and survival has improved. However they remain at risk of relapse and also of treatment related mortality. These findings emphasise the need for both intensive chemotherapy and optimal supportive care.Keywords
This publication has 20 references indexed in Scilit:
- Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocolBritish Journal of Haematology, 2001
- Progressive reduction in treatment‐related deaths in Medical Research Council childhood lymphoblastic leukaemia trials from 1980 to 1997 (UKALL VIII, X and XI)British Journal of Haematology, 2001
- Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trialsLeukemia, 2000
- Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia Trial XI (MRC UKALLXI)Leukemia, 1998
- Down’s syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trialsLeukemia, 1998
- Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL XBritish Journal of Haematology, 1997
- Treatment related deaths during induction and in first remission in acute lymphoblastic leukaemia: MRC UKALL X.Archives of Disease in Childhood, 1996
- Prognosis of Down's syndrome with acute leukaemia.Archives of Disease in Childhood, 1990
- Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemiaThe Journal of Pediatrics, 1987
- Down syndrome and acute leukemia in children: A 10-year retrospective survey from Childrens Cancer Study GroupThe Journal of Pediatrics, 1984